Year: 2025

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Written by Customer Service on November 4, 2025. Posted in Mergers And Acquisitions.

MELBOURNE, Australia, Nov. 04, 2025 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced a strategic initiative to pursue the acquisition of Digital Asset Treasury (DAT) companies that are currently trading below their Market Cap to Net Asset Value (MNAV). The Company’s management believes that acquiring undervalued DAT entities presents a compelling opportunity to strengthen Propanc’s balance sheet, diversify its asset base, and create long-term shareholder value. These DAT companies typically hold substantial reserves of leading digital assets such as Bitcoin (BTC) and Ethereum (ETH) on their balance sheets. According to public filings and data compiled by CoinMarketCap.com,...

Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical

Written by Customer Service on November 4, 2025. Posted in Mergers And Acquisitions.

QOL Medical to Acquire All Outstanding Shares of Evoke for $11.00 Per Share in Cash Represents a 139.7% premium to most recent Nasdaq closing price Transaction expected to close by the end of 2025 SOLANA BEACH, Calif., and VERO BEACH, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK) (“Evoke”), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, and QOL Medical, LLC (“QOL Medical”), a privately held biopharmaceutical company specializing in treatments for GI and rare diseases, today announced that they have entered into a definitive agreement pursuant to which QOL Medical will acquire Evoke for $11.00 per share in cash at closing. The transaction has been unanimously approved by the Boards of Directors...

InspireMD Reports Third Quarter 2025 Financial Results

Written by Customer Service on November 4, 2025. Posted in Earnings Releases And Operating Results.

Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the third quarter and nine months ended September 30, 2025. Recent Business Highlights:Initiated U.S. commercial launch of the CGuard Prime carotid stent system Completed over 100 U.S. carotid procedures across leading hospitals Strengthened leadership team with the appointment of Peter A. Soukas, M.D., as Chief Medical Officer Appointed Dan Dearen to the Board of Directors as Audit Committee Chairman bringing valuable experience to InspireMDMarvin Slosman, CEO of InspireMD, commented: “Our business demonstrated...

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Written by Customer Service on November 4, 2025. Posted in Earnings Releases And Operating Results.

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate UpdateSharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau and a-synCash resources of CHF 108.5 million as of September 30, 2025, provide funding to the end of Q3 2027 excluding any income from potential milestones Peer-reviewed papers covering groundbreaking results including clinical data on ACI-35.030 (JNJ-64042056) published in eBioMedicine and preclinical data on first-in-class PET tracers for imaging TDP-43 pathology published in Nature Communications IND/CTA filing for small molecule NLRP3 inhibitor ACI-19764 and the start of IND-enabling studies for Morphomer-Tau aggregation inhibitor both expected by year-endLausanne, Switzerland, November 4, 2025...

LGI Homes, Inc. Reports Third Quarter 2025 Results

Written by Customer Service on November 4, 2025. Posted in Earnings Releases And Operating Results.

THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced financial results for the third quarter and the nine months ended September 30, 2025. “We are pleased with our third quarter results, which met our stated guidance and reflect the disciplined execution of our teams as we continue to deliver on our strategic objectives,” said Eric Lipar, Chairman and Chief Executive Officer of LGI Homes. “During the quarter, we closed 1,107 homes, including 42 currently and previously leased homes, generated $396.6 million in revenue, and delivered gross and adjusted gross margins within our guidance range. Our teams remained focused on driving leads, managing inventory, and executing on sales initiatives that directly contributed an 8.1% year-over-year increase and 43.9% sequential increase in...

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates

Written by Customer Service on November 4, 2025. Posted in Earnings Releases And Operating Results.

Third-quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 million As of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra providing protection into 2045 Launched Rezdiffra in Germany following European Commission approval Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion as of Sept. 30, 2025 Company to host conference call today, Nov. 4, 2025, at 8 a.m. ESTCONSHOHOCKEN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2025 financial results and provides...

Shoals Technologies Group, Inc. Reports Financial Results for Third Quarter 2025

Written by Customer Service on November 4, 2025. Posted in Earnings Releases And Operating Results.

– Record Quarterly Revenue of $135.8 million, an increase of 32.9% year over year – – Gross Margin of 37.0% – – Operating Profit of $18.7 million – – Adjusted EBITDA1 of $32.0 million – – Record Backlog and Awarded Orders of $720.9 million – – Provides Fourth Quarter and Full Year 2025 Revenue Outlook – PORTLAND, Tenn., Nov. 04, 2025 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a leading provider of electrical balance of system (“EBOS”) solutions and components for the global energy transition market, today announced results for its third quarter ended September 30, 2025. “I’m very pleased with our third quarter’s performance, delivering revenue above the high-end of our guided range, record backlog and awarded orders of $720.9 million, and a book to bill of 1.4. We are executing...

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Written by Customer Service on November 4, 2025. Posted in Earnings Releases And Operating Results.

– Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 – – Update on Phase 1b/2 clinical trial of WTX-330 and potential further development plan is expected to be provided later in the fourth quarter of 2025 – – WTX-1011, Company’s first INDUCER™ T-cell engager development candidate targeting STEAP1, continues IND-enabling studies – WATERTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today...

Parex Resources Announces Third Quarter Results, Strong October 2025 Production, and Declaration of Q4 2025 Dividend

Written by Customer Service on November 4, 2025. Posted in Dividend Reports And Estimates.

CALGARY, Alberta, Nov. 04, 2025 (GLOBE NEWSWIRE) — Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) is pleased to announce its financial and operating results for the three-month period ended September 30, 2025, the declaration of its Q4 2025 regular dividend of C$0.385 per share, as well as an operational update. All amounts herein are in United States Dollars (“USD”) unless otherwise stated. “As we advance our 2025 plan, strong operational execution is fueling steady production growth and setting the stage for a strong start to 2026,” commented Imad Mohsen, President & Chief Executive Officer. “Our robust base assets remain a reliable source of strong performance, in addition to top-tier operations at LLA-32, and continued near-field exploration success at LLA-74. We are encouraged by the progress in the VIM-1...

Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences

Written by Customer Service on November 4, 2025. Posted in Public Companies.

NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million. The royalty interest being sold stems from Blackstone’s 2020 financing collaboration with Alnylam, in which Blackstone invested to support AMVUTTRA’s pivotal Phase 3 HELIOS-B trial. AMVUTTRA is an FDA-approved RNAi therapeutic for the treatment of ATTR amyloidosis, a progressive, degenerative and fatal disease caused by misfolded proteins that accumulate in the nerves, heart and GI tract. “We are delighted to acquire a royalty interest in AMVUTTRA,” said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. “AMVUTTRA is a breakthrough RNAi therapeutic that delivers...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals